Product Images Metformin Hydrochloride

The table summarizes the mean percent changes in major lipid variables at the end of a 24-week study on metformin hydrochloride tablets extended release. The variables include total cholesterol, total triglycerides, LDL-cholesterol, and HDL-cholesterol. The table shows the mean percent changes from baseline at the final visit for three different doses of metformin hydrochloride tablets, indicating their effectiveness in managing lipid levels.*

The text is a summary of changes in Hemoglobin A1c, Fasting Plasma Glucose, and Body Weight at Week 12 and the Final Visit (24-week study) in patients taking Metformin Hydrochloride tablets with varying doses. There are tables with baseline values as well as changes at different time points for each variable. The number of patients tested for each dose and time point is also provided.*

Table 4 provides a summary of mean percent change from baseline of major serum lipid variables at the final visit (29-week studies). The table compares the effects of Metformin Hydrochloride Tablets and Placebo, as well as the effects of Combined Metformin Hydrochloride Tablets/Glyburide to Monotherapy. The variables analyzed include Total Cholesterol, Total Triglycerides, LDL-Cholesterol, and HDL-Cholesterol. The table presents the baseline levels and mean percentage change at the final visit for each variable and treatment group.*

NuCare Pharmaceuticals, Inc. is a pharmaceutical company that produces Metformin HCI 500mg tablets in bottles of 180. The lot number of the bottle is 000000, and the expiry date is not available. The product is available on prescription only through a pharmacist. The product comes in a round white/soft-white tablet that is identified by a debossing "*H/102" on one side. The bottle states a warning to keep out of reach of children and to store at a controlled temperature between 59-86°F.*

This text provides information about a group of pediatric patients who were on a diet therapy at baseline. The mean age of the patients was 13.8 years, with a range between 10 to 16 years. However, the note indicates that some statistical measurements were not significant.*

This is a summary table comparing the effect of a drug (Metformin Hydrochloride Tablets) against Placebo in a 29-week study. The table presents the mean changes from baseline in three parameters, namely, Fasting Plasma Glucose, HbA, and Body Weight. A total of 145 patients were on the drug, while 141 on Placebo. The results indicate an improvement in FPG and Hemoglobin A% in the drug group while Bodyweight was not statistically significant. All the participants were undergoing diet therapy at the baseline.*

This table presents the comparison between Metformin Hydrochloride Tablets and Placebo in terms of their effects on plasma glucose and body weight in pediatric patients. It shows the mean changes from baseline to final visit for both groups. Metformin Hydrochloride tablets showed a significant decrease in plasma glucose and body weight compared to the placebo group. However, the p-value for body weight change was not significant.*

The table shows the comparison of Combined Metformin Hydrochloride Tablets/Glyburide (Comb) versus Glyburide (Glyb) or Metformin Hydrochloride Tablets (MET) Monotherapy in a 23-week study. The mean changes from baseline for Fasting Plasma Glucose, Hemoglobin A, and Body Weight are summarized. The results show the p-values for Glyb vs Comb, MET vs Comb, and MET vs Glyb. All patients were on 20 mg/day of glyburide at baseline. The data suggest that the combination therapy was more effective than monotherapy in reducing Fasting Plasma Glucose, Hemoglobin A but had no significant effect on body weight.*

This is a table showing a summary of mean changes from baseline in hemoglobin A1c (HbA1c) and daily insulin dose for patients who took combined Metformin Hydrochloride Tablets/Insulin compared to those who took a placebo. The table indicates that the Metformin Hydrochloride Tablets/Insulin group had a statistically significant decrease in HbA1c and a smaller increase in daily insulin dose compared to the placebo group.*